Caution: ibrutinib in patients with cardiac risk
Ibrutinib raises the risk of irregular heart rhythm, high blood pressure, and sudden cardiac events; second-generation BTK inhibitors are safer choices for patients with heart disease.
Atrial fibrillation 10-16%, hypertension ~40% cumulative, and ventricular arrhythmia/sudden death signals in long-term ibrutinib data; ELEVATE-RR and ALPINE showed roughly half the atrial fibrillation with acalabrutinib and zanubrutinib. Anticoagulation for AF adds bleeding risk with any BTKi.
Pages like this
not linked directly; found by shared links- TrialBELLWAVE-011
Shares Acalabrutinib, Ibrutinib, Chronic lymphocytic leukaemia.
- Key paperELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLL
Shares Acalabrutinib, Zanubrutinib, Ibrutinib, Chronic lymphocytic leukaemia.
- PairingBTK inhibitor + venetoclax, fixed duration
Shares Acalabrutinib, Zanubrutinib, Ibrutinib, Chronic lymphocytic leukaemia.
- TrialRESONATE
Shares Ibrutinib, Chronic lymphocytic leukaemia.
- InstitutionThe Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
Shares Acalabrutinib, Ibrutinib, Chronic lymphocytic leukaemia.
- TrialELEVATE-TN
- PairingCaution: chemoimmunotherapy in del(17p)/TP53 CLL
- TermRichter transformation